ELVAF Stock Chart & Stats
$2.15
$0.00(0.00%)
At close: 4:00 PM EDT
$2.15
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.90 - $2.15
Previous CloseN/A
Volume20.00
Average Volume (3M)0.00
Market Cap
$19.89M
Enterprise Value$0.23
Total Cash (Recent Filing)$5.61M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.22
Next Earnings
Feb 19, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding7,230,626
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.98
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)3.15
Revenue Forecast (FY)$76.74M
Bulls Say, Bears Say
Bulls Say
Low LeverageThe absence of reported debt limits interest-bearing obligations and reduces balance-sheet strain. This gives Evolva greater financial flexibility than a highly leveraged company, although the benefit is tempered by declining assets, equity, and ongoing operating losses.
Reduced Cash BurnA meaningful reduction in cash burn improves near-term financial endurance and could slow depletion of available resources. However, the improvement is not yet equivalent to self-funding operations because operating and free cash flow remained negative throughout the period shown.
Biotechnology PlatformEvolva’s biotechnology and fermentation focus provides a potentially differentiated platform for specialty ingredients in nutrition, health, and wellness. Product development and intellectual-property licensing can support scalable commercialization if the company re-establishes operating activity and revenue.
Bears Say
No Operating RevenueZero reported revenue removes the current operating scale needed to support recurring expenses, product investment, and commercial expansion. Unless revenue-generating activity resumes, the company has limited evidence of an active business engine capable of producing durable growth.
Persistent Cash ConsumptionSustained negative operating and free cash flow means the business has not demonstrated the ability to fund itself through operations. Continued cash consumption can constrain investment, increase reliance on financing or asset reductions, and weaken resilience over the coming quarters.
Unstable ProfitabilityThe reversal from 2024 profit to 2025 losses indicates that profitability was not sustained. Combined with a materially shrinking asset and equity base, this points to unstable value creation and reduces the financial foundation available to support future operations.
Evolva Holding News
ELVAF FAQ
What was Evolva Holding’s price range in the past 12 months?
Evolva Holding lowest stock price was $0.90 and its highest was $2.15 in the past 12 months.
What is Evolva Holding’s market cap?
Evolva Holding’s market cap is $19.89M.
When is Evolva Holding’s upcoming earnings report date?
Evolva Holding’s upcoming earnings report date is Feb 19, 2027 which is in 159 days.
How were Evolva Holding’s earnings last quarter?
Evolva Holding released its earnings results on Apr 29, 2026. The company reported -$0.05 earnings per share for the quarter.
Is Evolva Holding overvalued?
According to Wall Street analysts Evolva Holding’s price is currently Overvalued.
Does Evolva Holding pay dividends?
Evolva Holding does not currently pay dividends.
What is Evolva Holding’s EPS estimate?
Evolva Holding’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Evolva Holding have?
Evolva Holding has 7,230,626 shares outstanding.
What happened to Evolva Holding’s price movement after its last earnings report?
Evolva Holding reported an EPS of -$0.05 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Evolva Holding?
Currently, no hedge funds are holding shares in ELVAF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Evolva Holding
EvoNext Holdings SA is dedicated to the exploration, creation, and distribution of pioneering ingredients across the nutritional, health, and wellness domains. Founded in 2004, the company's inception is attributed to Alexandra Santana Sørensen, Søren V. S. Nielsen, and Neil Goldsmith. Its corporate headquarters are located in Reinach, Switzerland.
Technical Analysis
Molecular Partners AG
―
Lonza Group Ltd
―
Bachem Holding AG
―
Kuros Biosciences
―
Xlife Sciences Ltd.
―
Ownership Overview
―
Insiders
― Other Institutional Investors
99.79% Public Companies and
Individual Investors